Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

198.41USD
16 Oct 2017
Change (% chg)

$-7.11 (-3.46%)
Prev Close
$205.52
Open
$205.55
Day's High
$206.93
Day's Low
$192.10
Volume
9,525,485
Avg. Vol
2,283,172
52-wk High
$256.80
52-wk Low
$184.50

Select another date:

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

UPDATE 3-U.S. judge in Texas invalidates Allergan patents on Restasis

Oct 16 A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

BRIEF-U.S. Court issues adverse decision concerning Allergan's Restasis

* U.S. District Court for the Eastern District of Texas issues adverse trial decision concerning Restasis (cyclosporine ophthalmic emulsion) 0.05% patents

U.S. judge in Texas invalidates Allergan patents on Restasis

Oct 16 A U.S. judge on Monday invalidated patents issued to Allergan Plc on its dry eye medicine Restasis, saying they covered ideas that were too obvious to protect.

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

Allergan settles with one of four companies contesting Restasis patent

Oct 12 Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

BRIEF-Allergan announces settlement on Restasis patent litigation with Innopharma

* Allergan announces settlement on Restasis® (cyclosporine ophthalmic emulsion) 0.05% patent litigation with Innopharma, Inc.

Texas judge poised to decide if Allergan patent deal with Mohawks was a sham

Last month, in the midst of post-trial briefing in Allergan’s patent suit against generic drug makers that want to begin selling a version of Allergan’s dry eye medication Restasis, Allergan sent a one-paragraph letter to U.S. District Judge William Bryson of Marshall, Texas. Allergan informed the judge that it had just assigned its rights to the patents at issue in the case to the Saint Regis Mohawk Tribe, which, in turn, had granted Allergan an exclusive license to the patents. All

Allergan's Forest to pay $4 million to settle gender discrimination case

Allergan Plc's Forest Laboratories unit has agreed to pay $4 million to resolve a lawsuit claiming the drugmaker discriminated against female sales representatives, according to court papers.

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

Select another date: